{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:53:33Z","timestamp":1785887613192,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangxi Natural Science Foundation under Grant","award":["2024GXNSFBA010070"],"award-info":[{"award-number":["2024GXNSFBA010070"]}]},{"name":"Guangxi Natural Science Foundation Joint Special Project on Active Health and Common Diseases","award":["2024GXNSFBA010103"],"award-info":[{"award-number":["2024GXNSFBA010103"]}]},{"name":"Guangxi Young Elite Scientist Sponsorship Program","award":["GXYESS2025053"],"award-info":[{"award-number":["GXYESS2025053"]}]},{"name":"Guangxi Zhuang Autonomous Region Disease Prevention and Control Science and Technology Project","award":["GXJKKJ2025ZC048"],"award-info":[{"award-number":["GXJKKJ2025ZC048"]}]},{"name":"High-level Talent Scientific Research Startup Fund of People\u2019s Hospital of Guangxi Zhuang Autonomous Region","award":["YKY-GCRC-202508"],"award-info":[{"award-number":["YKY-GCRC-202508"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-026-03197-z","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:03:03Z","timestamp":1780153383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The evolution of EBV DNA as a biomarker in nasopharyngeal carcinoma immunotherapy: a bibliometric and knowledge mapping analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qicong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosu","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taicheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"11","key":"3197_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol. 2021;18(11):679\u201395.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10445","key":"3197_CR2","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","volume":"403","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2024;403(10445):2720\u201331.","journal-title":"Lancet"},{"key":"3197_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.6245","author":"Y Huang","year":"2026","unstructured":"Huang Y, Sun D, Zhou H, Zhou T, Qu S, Li J, et al. Five-year outcome of camrelizumab plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a secondary analysis of the CAPTAIN-1st randomized clinical trial. JAMA Oncol. 2026. https:\/\/doi.org\/10.1001\/jamaoncol.2025.6245.","journal-title":"JAMA Oncol"},{"issue":"1","key":"3197_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-04049-y","volume":"16","author":"J Gao","year":"2025","unstructured":"Gao J, Zong D, He Y, Xu J, He X. Efficacy and safety of PD-1 inhibitors combined with anti-angiogenic agents in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Discov Oncol. 2025;16(1):2204.","journal-title":"Discov Oncol"},{"key":"3197_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.107129","volume":"160","author":"H Li","year":"2025","unstructured":"Li H, Lou L, Du J, Li M, Wen X, Zhang Y, et al. Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma. Oral Oncol. 2025;160:107129.","journal-title":"Oral Oncol"},{"issue":"9","key":"3197_CR6","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.21037\/tcr-2025-393","volume":"14","author":"S Wang","year":"2025","unstructured":"Wang S, Fu W, Ge S, Wang X, Xue B, Li G. An immune-related miRNA signature predicts the prognosis in nasopharyngeal carcinoma. Transl Cancer Res. 2025;14(9):5873\u201383.","journal-title":"Transl Cancer Res"},{"issue":"6","key":"3197_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"3197_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cncr.31741","volume":"125","author":"R Guo","year":"2019","unstructured":"Guo R, Tang LL, Mao YP, Du XJ, Chen L, Zhang ZC, et al. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer. 2019;125(1):79\u201389.","journal-title":"Cancer"},{"issue":"1","key":"3197_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/v15010066","volume":"15","author":"A Gihbid","year":"2022","unstructured":"Gihbid A, Benzeid R, Faouzi A, El Alami I, Tawfiq N, Benchakroun N, et al. The dynamic change in plasma Epstein-Barr virus DNA load over a long-term follow-up period predicts prognosis in nasopharyngeal carcinoma. Viruses. 2022;15(1):66.","journal-title":"Viruses"},{"issue":"9","key":"3197_CR10","doi-asserted-by":"publisher","first-page":"BSR20190691","DOI":"10.1042\/BSR20190691","volume":"39","author":"H Peng","year":"2019","unstructured":"Peng H, Li Z, Long Y, Li J, Liu Z, Zhou R. Clinical value of a plasma Epstein-Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis. Biosci Rep. 2019;39(9):BSR20190691.","journal-title":"Biosci Rep"},{"issue":"3","key":"3197_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0587","volume":"5","author":"JY Xu","year":"2022","unstructured":"Xu JY, Wei XL, Ren C, Zhang Y, Hu YF, Li JY, et al. Association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy. JAMA Netw Open. 2022;5(3):e220587.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"3197_CR12","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.3390\/cancers15061887","volume":"15","author":"S Mahajan","year":"2023","unstructured":"Mahajan S, Balcioglu HE, Oostvogels A, Dik WA, Chan KCA, Lo KW, et al. Frequency of peripheral CD8+ T cells expressing chemo-attractant receptors CCR1, 4 and 5 increases in NPC patients with EBV clearance upon radiotherapy. Cancers (Basel). 2023;15(6):1887.","journal-title":"Cancers (Basel)"},{"key":"3197_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/82_2025_337","author":"LF Walsh","year":"2026","unstructured":"Walsh LF, Xian RR, Ambinder RF. The biology and clinical utility of EBV monitoring in blood. Curr Top Microbiol Immunol. 2026. https:\/\/doi.org\/10.1007\/82_2025_337.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"3","key":"3197_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40037-021-00695-4","volume":"11","author":"A Ninkov","year":"2022","unstructured":"Ninkov A, Frank JR, Maggio LA. Bibliometrics: methods for studying academic publishing. Perspect Med Educ. 2022;11(3):173\u20136.","journal-title":"Perspect Med Educ"},{"issue":"1","key":"3197_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2360341","volume":"20","author":"G Wang","year":"2024","unstructured":"Wang G, Zou X, Weng J, Lan G, Li M, Wei J, et al. Bibliometric analysis reveals the research hotspots and trends of nasopharyngeal carcinoma immunotherapy. Hum Vaccin Immunother. 2024;20(1):2360341.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"3197_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49636-7","volume":"13","author":"Y Tian","year":"2023","unstructured":"Tian Y, Liu J, Xu X, Wu X. Knowledge mapping of vocational education and training research (2004-2020): a visual analysis based on citespace. Sci Rep. 2023;13(1):22348.","journal-title":"Sci Rep"},{"key":"3197_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mex.2025.103622","volume":"15","author":"HY Chuang","year":"2025","unstructured":"Chuang HY, Chou W. SilhouetteScoreinR: beyond traditional network layouts by leveraging local cohesion and nearest neighbor separation. MethodsX. 2025;15:103622.","journal-title":"MethodsX"},{"key":"3197_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1195659","volume":"14","author":"H Huang","year":"2023","unstructured":"Huang H, Yao Y, Deng X, Weng H, Chen Z, Yu L, et al. Characteristics of immunotherapy trials for nasopharyngeal carcinoma over a 15-year period. Front Immunol. 2023;14:1195659.","journal-title":"Front Immunol"},{"key":"3197_CR19","doi-asserted-by":"publisher","first-page":"1212813","DOI":"10.3389\/fphar.2023.1212813","volume":"14","author":"Z Dai","year":"2023","unstructured":"Dai Z, Li N, Wang J, Tan C, Zhang Y, Liu L. Anti-PD-1\/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov. Front Pharmacol. 2023;14:1212813.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3197_CR20","doi-asserted-by":"publisher","first-page":"djx007","DOI":"10.1093\/jnci\/djx007","volume":"109","author":"KY Kim","year":"2017","unstructured":"Kim KY, Le QT, Yom SS, Pinsky BA, Bratman SV, Ng RH, et al. Current state of PCR-based Epstein-Barr virus DNA testing for nasopharyngeal cancer. J Natl Cancer Inst. 2017;109(4):djx007.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"3197_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1089\/gtmb.2018.0304","volume":"23","author":"X Xie","year":"2019","unstructured":"Xie X, Ren Y, Wang K, Yi B. Molecular prognostic value of circulating Epstein-Barr viral DNA in nasopharyngeal carcinoma: a meta-analysis of 27,235 cases in the endemic area of Southeast Asia. Genet Test Mol Biomarkers. 2019;23(7):448\u201359.","journal-title":"Genet Test Mol Biomarkers"},{"issue":"7","key":"3197_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"FH Wang","year":"2021","unstructured":"Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, et al. Efficacy, safety, and correlative biomarkers of Toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;39(7):704\u201312.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3197_CR23","doi-asserted-by":"publisher","first-page":"e003790","DOI":"10.1136\/jitc-2021-003790","volume":"9","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zhou T, Chen X, Li J, Pan J, He X, et al. Efficacy, safety, and biomarker analysis of camrelizumab in Previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study). J Immunother Cancer. 2021;9(12):e003790.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3197_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell. 2023;41(6):1061-1072.e1064.","journal-title":"Cancer Cell"},{"issue":"6","key":"3197_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105295","volume":"10","author":"SQ He","year":"2025","unstructured":"He SQ, Lv SH, Wen SQ, Wang L, Zhao ZY, Bei WX, et al. The efficacy of immunotherapy combined with capecitabine versus immunotherapy alone as maintenance therapy in patients with de novo metastatic nasopharyngeal carcinoma: a retrospective propensity score matching study. ESMO Open. 2025;10(6):105295.","journal-title":"ESMO Open"},{"issue":"3","key":"3197_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12032-025-02610-x","volume":"42","author":"JKK Mark","year":"2025","unstructured":"Mark JKK, Teh AH, Yap BK. Epstein-Barr virus-infected nasopharyngeal carcinoma therapeutics: oncoprotein targets and clinical implications. Med Oncol. 2025;42(3):59.","journal-title":"Med Oncol"},{"issue":"8","key":"3197_CR27","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ccell.2024.07.001","volume":"42","author":"J Lv","year":"2024","unstructured":"Lv J, Xu LX, Li ZX, Lin L, Wu CF, Quan TQ, et al. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: the EP-SEASON study. Cancer Cell. 2024;42(8):1401-1414.e1404.","journal-title":"Cancer Cell"},{"key":"3197_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117386","volume":"287","author":"N Oumata","year":"2025","unstructured":"Oumata N, Zhong Q, Zhang Y, Galons H, Andrei G, Zeng M. Emerging drugs for Epstein-Barr virus associated-diseases. Eur J Med Chem. 2025;287:117386.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"3197_CR29","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/med.22104","volume":"45","author":"J Wang","year":"2025","unstructured":"Wang J, Wang R, Wang M, Ge J, Wang Y, Li Y, et al. Cutting-edge therapy and immune escape mechanisms in EBV-associated tumors. Med Res Rev. 2025;45(4):1184\u2013210.","journal-title":"Med Res Rev"},{"key":"3197_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1582774","volume":"16","author":"J Chen","year":"2025","unstructured":"Chen J, Cheng X. Nanomaterials and immune checkpoint inhibitors in cancer immunotherapy: the synergistic innovation prospects. Front Immunol. 2025;16:1582774.","journal-title":"Front Immunol"},{"issue":"1","key":"3197_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38396-z","volume":"13","author":"Q He","year":"2023","unstructured":"He Q, Huang Y, Yuan L, Wang Z, Wang Q, Liu D, et al. A promising predictive biomarker combined EBV NDA with PNI for nasopharyngeal carcinoma in nonendemic area of China. Sci Rep. 2023;13(1):11700.","journal-title":"Sci Rep"},{"issue":"9","key":"3197_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.24721","volume":"4","author":"WZ Li","year":"2021","unstructured":"Li WZ, Wu HJ, Lv SH, Hu XF, Liang H, Liu GY, et al. Assessment of survival model performance following inclusion of Epstein-Barr virus DNA status in conventional TNM staging groups in Epstein-Barr virus-related nasopharyngeal carcinoma. JAMA Netw Open. 2021;4(9):e2124721.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"3197_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71496","volume":"15","author":"ATC Chan","year":"2026","unstructured":"Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Spreafico A, et al. Analysis of plasma Epstein-Barr virus DNA and clinical outcomes to Pembrolizumab or chemotherapy in recurrent\/metastatic nasopharyngeal cancer in KEYNOTE-122. Cancer Med. 2026;15(2):e71496.","journal-title":"Cancer Med"},{"key":"3197_CR34","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.2147\/JIR.S512808","volume":"18","author":"M Fang","year":"2025","unstructured":"Fang M, Hu Y, Wang T, Su Y, Lu T, Zhang H, et al. Integrated early CRP kinetics and plasma EBV DNA clearance as prognostic biomarkers in de novo metastatic nasopharyngeal carcinoma treated with first-line chemoimmunotherapy. J Inflamm Res. 2025;18:6783\u201394.","journal-title":"J Inflamm Res"},{"issue":"1","key":"3197_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12564-4","volume":"24","author":"S Lin","year":"2024","unstructured":"Lin S, Zhou H, Chen G, Xue J, Liu Q, Li J, et al. Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy. BMC Cancer. 2024;24(1):797.","journal-title":"BMC Cancer"},{"key":"3197_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115098","volume":"213","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Zhu L, Lv W, Xu T, Shen C, Qian W, et al. Liquid biopsy with plasma Epstein-Barr virus DNA characterizes biological relapse for the prediction of cancer recurrence in non-disseminated nasopharyngeal carcinoma. Eur J Cancer. 2024;213:115098.","journal-title":"Eur J Cancer"},{"issue":"12","key":"3197_CR37","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1016\/S1470-2045(22)00505-8","volume":"23","author":"VH Lee","year":"2022","unstructured":"Lee VH, Adham M, Ben Kridis W, Bossi P, Chen MY, Chitapanarux I, et al. International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic. Lancet Oncol. 2022;23(12):e544\u201351.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3197_CR38","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/diagnostics13030476","volume":"13","author":"M Rzepka","year":"2023","unstructured":"Rzepka M, Depka D, Gospodarek-Komkowska E, Bogiel T. Diagnostic value of whole-blood and plasma samples in Epstein-Barr virus infections. Diagnostics (Basel). 2023;13(3):476.","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"3197_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/pathogens9030226","volume":"9","author":"MAH AbuSalah","year":"2020","unstructured":"AbuSalah MAH, Gan SH, Al-Hatamleh MAI, Irekeola AA, Shueb RH, Yean Yean C. Recent advances in diagnostic approaches for Epstein-Barr virus. Pathogens. 2020;9(3):226.","journal-title":"Pathogens"},{"issue":"9","key":"3197_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105763","volume":"10","author":"G Wang","year":"2025","unstructured":"Wang G, Qin J, Nong W, Ma D, Wang C, Yu H, et al. Consensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in China. ESMO Open. 2025;10(9):105763.","journal-title":"ESMO Open"},{"issue":"5","key":"3197_CR41","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1007\/s11192-022-04289-7","volume":"127","author":"M Gusenbauer","year":"2022","unstructured":"Gusenbauer M. Search where you will find most: comparing the disciplinary coverage of 56 bibliographic databases. Scientometrics. 2022;127(5):2683\u2013745.","journal-title":"Scientometrics"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03197-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03197-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03197-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:30:47Z","timestamp":1785886247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03197-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3197"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03197-z","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As this study does not involve animal and patient experiments, the ethical approval and consent to participate are not necessary.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"186"}}